

MD7510 Clinical Presentation & Management in Diabetes: Glycaemic Control, New & Novel Therapies (DL)

[View Online](#)

1.

Diagnosis and management of type 1 diabetes in children, young people and adults | Guidance and guidelines | NICE [Internet]. Available from: <https://www.nice.org.uk/guidance/cg15>

2.

Type 2 diabetes in adults: management | Guidance and guidelines | NICE [Internet]. Available from: <https://www.nice.org.uk/guidance/ng28>

3.

Efficacy and Safety of Glucagon-like peptide-1 receptor agonists in type 2 diabetes Systematic review and mixed-treatment comparison analysis [Internet]. Available from: <http://onlinelibrary.wiley.com.ezproxy3.lib.le.ac.uk/doi/10.1111/dom.12849/epdf>

4.

Obesity: identification, assessment and management | Guidance and guidelines | NICE [Internet]. Available from: <https://www.nice.org.uk/guidance/cg189>

5.

Managing Older People with Type 2 Diabetes: IDF Global Guideline - International Federation on Ageing [Internet]. Available from: <https://www.ifa-fiv.org/managing-older-people-with-type-2-diabetes-idf-global-guideline/>

6.

NHS Evidence: an introduction [Internet]. Available from:
http://www.solent.nhs.uk/_store/documents/nhs_evidence_guide.pdf

7.

Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. Textbook of Diabetes [Internet]. 5th ed. Somerset: John Wiley & Sons, Incorporated; 2016. Available from:
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

8.

Holt RIG. Textbook of diabetes [Internet]. 4th ed. Chichester: Wiley-Blackwell; 2010. Available from: <http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

9.

Atkinson MA. The Pathogenesis and Natural History of Type 1 Diabetes. Cold Spring Harbor Perspectives in Medicine. 2012 Nov 1;2(11):a007641–a007641. doi:10.1101/cshperspect.a007641

10.

Jelinek HF, Stranieri A, Yatsko A, Venkatraman S. Data analytics identify glycated haemoglobin co-markers for type 2 diabetes mellitus diagnosis. Computers in Biology and Medicine. 2016 Aug;75:90–7. doi:10.1016/j.combiomed.2016.05.005

11.

S M Attard. Implications of iron deficiency/anemia on the classification of diabetes using HbA1c. Nutrition & Diabetes. 2015;5(6). doi:doi: 10.1038/nutd.2015.16

12.

Samuel VT, Shulman GI. Integrating Mechanisms for Insulin Resistance: Common Threads and Missing Links. Cell. 2012 Mar;148(5):852–71. doi:10.1016/j.cell.2012.02.017

13.

Beverley M Shields. Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature. *BMJ Open*. 2015;5(11). doi:doi:10.1136/bmjopen-2015-009088

14.

Zaccardi F, Webb DR, Yates T, Davies MJ. Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. *Postgraduate Medical Journal*. 2016 Feb;92(1084):63–9. doi:10.1136/postgradmedj-2015-133281

15.

Anthony H. Barnett, Jenny Grice. *New Mechanisms in Glucose Control* [Internet]. BMJ Books; 1 edition; 2013. Available from: <http://ezproxy.lib.le.ac.uk/login?url=http://lib.myilibrary.com?id=478133>

16.

Gregg EW. The Changing Tides of the Type 2 Diabetes Epidemic—Smooth Sailing or Troubled Waters Ahead? Kelly West Award Lecture 2016. *Diabetes Care*. 2017 Aug 10. doi:10.2337/dci16-0055

17.

Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. *Textbook of Diabetes* [Internet]. 5th ed. Somerset: John Wiley & Sons, Incorporated; 2016. Available from: <http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

18.

Holt RIG. *Textbook of diabetes* [Internet]. 4th ed. Chichester: Wiley-Blackwell; 2010. Available from: <http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

19.

Copeland KC, Silverstein J, Moore KR, Prazar GE, Raymer T, Shiffman RN, et al. Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents. *PEDIATRICS*. 2013 Feb 1;131(2):364–82. doi:10.1542/peds.2012-3494

20.

Kenneth Hodson. Gestational diabetes: emerging concepts in pathophysiology. *Obstetric Medicine*. 2010;3(4). doi:doi: 10.1258/om.2010.100025

21.

Latika Sahu. Comparison of the American Diabetes Association and World Health Organization criteria for gestational diabetes mellitus and the outcomes of pregnancy. *Obstetric Medicine*. 2009;2(4). doi:doi: 10.1258/om.2009.080049

22.

Schwartz SS, Epstein S, Corkey BE, Grant SFA, Gavin JR, Aguilar RB. The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β -Cell-Centric Classification Schema. *Diabetes Care*. 2016 Feb;39(2):179–86. doi:10.2337/dc15-1585

23.

Nolan CJ, Ruderman NB, Kahn SE, Pedersen O, Prentki M. Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes. *Diabetes*. 2015 Mar;64(3):673–86. doi:10.2337/db14-0694

24.

Gale EA. Is type 2 diabetes a category error? *The Lancet*. 2013 Jun;381(9881):1956–7. doi:10.1016/S0140-6736(12)62207-7

25.

Moreno-Castilla C, Mauricio D, Hernandez M. Role of Medical Nutrition Therapy in the Management of Gestational Diabetes Mellitus. *Current Diabetes Reports*. 2016 Apr;16(4). doi:10.1007/s11892-016-0717-7

26.

Noctor E, Dunne F. Postnatal testing following gestational diabetes. *The Lancet Diabetes & Endocrinology*. 2015 Oct;3(10):761–2. doi:10.1016/S2213-8587(15)00322-8

27.

Birkeland KI. Hyperglycaemia in pregnancy: still a lot to learn. *The Lancet Diabetes & Endocrinology*. 2015 Oct;3(10):752–3. doi:10.1016/S2213-8587(15)00282-X

28.

Rinki Murphy. Monogenic diabetes and pregnancy. *Obstetric Medicine*. 2015;8(3). doi:doi:10.1177/1753495X15590713

29.

Stewart ZA, Wilinska ME, Hartnell S, Temple RC, Rayman G, Stanley KP, et al. Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. *New England Journal of Medicine*. 2016 Aug 18;375(7):644–54. doi:10.1056/NEJMoa1602494

30.

Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period (NG3 [Internet]. Available from: <https://www.nice.org.uk/guidance/ng3>

31.

Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. *Diabetic Medicine*. 2013 Jul;30(7):803–17. doi:10.1111/dme.12159

32.

Unit 3 – Special care groups: A practical guide to pregnancy complicated by diabetes - Diabetes & Primary Care [Internet]. Available from: <http://www.diabetesandprimarycare.co.uk/journal-content/view/unit-3-special-care-groups-a-practical-guide-to-pregnancy-complicated-by-diabetes/?preview>

33.

Brown J, Alwan NA, West J, Brown S, McKinlay CJ, Farrar D, et al. Lifestyle interventions for the treatment of women with gestational diabetes. In: Cochrane Database of Systematic Reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 1996. Available from: <http://doi.wiley.com/10.1002/14651858.CD011970.pub2>
doi:10.1002/14651858.CD011970.pub2

34.

Rasouli B, Andersson T, Carlsson PO, Hjort R, Löfvenborg JE, Martinell M, et al. Serious life events and the risk of latent autoimmune diabetes in adults (LADA) and Type 2 diabetes. *Diabetic Medicine*. 2017 Sep;34(9):1259–63. doi:10.1111/dme.13410

35.

Davies M, Dahl D, Heise T, Kiljanski J, Mathieu C. Introduction of biosimilar insulins in Europe. *Diabetic Medicine*. 2017 Oct;34(10):1340–53. doi:10.1111/dme.13400

36.

Perrin NE, Davies MJ, Robertson N, Snoek FJ, Khunti K. The prevalence of diabetes-specific emotional distress in people with Type 2 diabetes: a systematic review and meta-analysis. *Diabetic Medicine*. 2017 Nov;34(11):1508–20. doi:10.1111/dme.13448

37.

Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. Textbook of Diabetes [Internet]. 5th ed. Somerset: John Wiley & Sons, Incorporated; 2016. Available from: <http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

38.

Holt RIG. Textbook of diabetes [Internet]. 4th ed. Chichester: Wiley-Blackwell; 2010. Available from: <http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

39.

Standards of Medical Care in Diabetes--2015: Summary of Revisions. *Diabetes Care*. 2015 Jan 1;38(Supplement_1):S4-S4. doi:10.2337/dc15-S003

40.

A Randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the Anglo-Danish-Dutch Study of intensive Treatment in People with Screen-Detected Diabetes in Primary care (ADDITION-Europe) study. [Internet]. Available from: <http://www.journalslibrary.nihr.ac.uk/hta/volume-20/issue-64#abstract>

41.

Kamlesh Khunti. Systematic Review and Meta-Analysis of Response Rates and Diagnostic Yield of Screening for Type 2 Diabetes and Those at High Risk of Diabetes. *PLoS ONE*. 2015;10(9). doi:doi: 10.1371/journal.pone.0135702

42.

Tao L, Wilson ECF, Wareham NJ, Sandbaek A, Rutten GEHM, Lauritzen T, et al. Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial. *Diabetic Medicine*. 2015 Jul;32(7):907-19. doi:10.1111/dme.12711

43.

Gray LJ, Khunti K, Wilmot EG, Yates T, Davies MJ. External validation of two diabetes risk scores in a young UK South Asian population. *Diabetes Research and Clinical Practice*. 2014 Jun;104(3):451-8. doi:10.1016/j.diabres.2014.03.018

44.

Gray LJ, Khunti K, Edwardson C, Goldby S, Henson J, Morris DH, et al. Implementation of the automated Leicester Practice Risk Score in two diabetes prevention trials provides a high yield of people with abnormal glucose tolerance. *Diabetologia*. 2012 Dec;55(12):3238-44. doi:10.1007/s00125-012-2725-8

45.

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*. 2015 Jan;38(1):140–9. doi:10.2337/dc14-2441

46.

Guidelines [Internet]. Available from:
<https://www.idf.org/e-library/guidelines/79-global-guideline-for-type-2-diabetes>

47.

Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. Textbook of Diabetes [Internet]. 5th ed. Somerset: John Wiley & Sons, Incorporated; 2016. Available from:
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

48.

Holt RIG. Textbook of diabetes [Internet]. 4th ed. Chichester: Wiley-Blackwell; 2010. Available from: <http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

49.

Holt RIG. Textbook of diabetes [Internet]. 4th ed. Chichester: Wiley-Blackwell; 2010. Available from: <http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

50.

Davies MJ, Heller S, Skinner TC, Campbell MJ, Carey ME, Cradock S, et al. Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. *BMJ*. 2008 Mar 1;336(7642):491–5. doi:10.1136/bmj.39474.922025.BE

51.

Johnston BC, Kanters S, Bandayrel K, Wu P, Naji F, Siemieniuk RA, et al. Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults. *JAMA*. 2014 Sep 3;312(9). doi:10.1001/jama.2014.10397

52.

Steven S, Hollingsworth KG, Al-Mrabeh A, Avery L, Aribisala B, Caslake M, et al. Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders. *Diabetes Care*. 2016 May;39(5):808-15. doi:10.2337/dc15-1942

53.

Steven S, Taylor R. Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration Type 2 diabetes. *Diabetic Medicine*. 2015 Sep;32(9):1149-55. doi:10.1111/dme.12722

54.

Amy Kennedy. Does Exercise Improve Glycaemic Control in Type 1 Diabetes? A Systematic Review and Meta-Analysis. *PLoS ONE*. 2013;8(3). doi:doi: 10.1371/journal.pone.0058861

55.

Chimen M, Kennedy A, Nirantharakumar K, Pang TT, Andrews R, Narendran P. What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review. *Diabetologia*. 2012 Mar;55(3):542-51. doi:10.1007/s00125-011-2403-2

56.

Umpierre D. Physical Activity Advice Only or Structured Exercise Training and Association With HbA_{1c} Levels in Type 2 Diabetes. *JAMA*. 2011 May 4;305(17). doi:10.1001/jama.2011.576

57.

Avery L, Flynn D, van Wersch A, Sniehotta FF, Trenell MI. Changing Physical Activity Behavior in Type 2 Diabetes: A systematic review and meta-analysis of behavioral

interventions. *Diabetes Care*. 2012 Dec 1;35(12):2681–9. doi:10.2337/dc11-2452

58.

Barry VW, Baruth M, Beets MW, Durstine JL, Liu J, Blair SN. Fitness vs. Fatness on All-Cause Mortality: A Meta-Analysis. *Progress in Cardiovascular Diseases*. 2014 Jan;56(4):382–90. doi:10.1016/j.pcad.2013.09.002

59.

Qin L, Knol MJ, Corpeleijn E, Stolk RP. Does physical activity modify the risk of obesity for type 2 diabetes: a review of epidemiological data. *European Journal of Epidemiology*. 2010 Jan;25(1):5–12. doi:10.1007/s10654-009-9395-y

60.

Lee IM. Physical Activity and Weight Gain Prevention. *JAMA*. 2010 Mar 24;303(12). doi:10.1001/jama.2010.312

61.

John M Jakicic. Physical activity considerations for the treatment and prevention of obesity. *The American Journal of Clinical Nutrition* [Internet]. 2005 Jan 7;82(1):226S-229S. Available from: <http://ajcn.nutrition.org/content/82/1/226S>

62.

Heinonen I, Helajärvi H, Pahkala K, Heinonen OJ, Hirvensalo M, Pälve K, et al. Sedentary behaviours and obesity in adults: the Cardiovascular Risk in Young Finns Study. *BMJ Open*. 2013 May;3(6). doi:10.1136/bmjopen-2013-002901

63.

Sallis JF, Bull F, Guthold R, Heath GW, Inoue S, Kelly P, et al. Progress in physical activity over the Olympic quadrennium. *The Lancet*. 2016 Sep;388(10051):1325–36. doi:10.1016/S0140-6736(16)30581-5

64.

Yeh JS, Kushner RF, Schiff GD. Obesity and Management of Weight Loss. *New England Journal of Medicine*. 2016 Sep 22;375(12):1187–9. doi:10.1056/NEJMc1de1515935

65.

Henson, Joseph. Associations of Sedentary Time with Fat Distribution in a High-Risk Population. [Internet]. 2014 Nov 10. Available from: <https://ira.le.ac.uk/handle/2381/32505>

66.

The Eatwell Guide [Internet]. Public Health England; 2016. Available from: <https://www.gov.uk/government/publications/the-eatwell-guide>

67.

Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (review) TA151, July 2008 [Internet]. Available from: <http://www.nice.org.uk/guidance/ta151>

68.

Hadjiconstantinou M, Byrne J, Bodicoat DH, Robertson N, Eborall H, Khunti K, et al. Do Web-Based Interventions Improve Well-Being in Type 2 Diabetes? A Systematic Review and Meta-Analysis. *Journal of Medical Internet Research*. 2016 Oct 21;18(10). doi:10.2196/jmir.5991

69.

Young-Hyman D, de Groot M, Hill-Briggs F, Gonzalez JS, Hood K, Peyrot M. Erratum. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. *Diabetes Care* 2016;39:2126–2140. *Diabetes Care*. 2017 Feb;40(2):287.1-287. doi:10.2337/dc17-er02

70.

Capehorn M, Polonsky WH, Edelman S, Belton A, Down S, Gamerman V, et al. Challenges faced by physicians when discussing the Type 2 diabetes diagnosis with patients: insights

from a cross-national study (IntroDia
doi:10.1111/dme.13357

). Diabetic Medicine. 2017 Mar.

71.

Hartman YAW, Jansen HJ, Hopman MTE, Tack CJ, Thijssen DHJ. Insulin-Associated Weight Gain in Type 2 Diabetes Is Associated With Increases in Sedentary Behavior. Diabetes Care. 2017 Sep;40(9):e120-1. doi:10.2337/dc17-0787

72.

Hessler DM, Fisher L, Polonsky WH, Masharani U, Strycker LA, Peters AL, et al. Diabetes distress is linked with worsening diabetes management over time in adults with Type 1 diabetes. Diabetic Medicine. 2017 Sep;34(9):1228-34. doi:10.1111/dme.13381

73.

Ferrari M, Dal Cin M, Steele M. Self-compassion is associated with optimum self-care behaviour, medical outcomes and psychological well-being in a cross-sectional sample of adults with diabetes. Diabetic Medicine. 2017 Nov;34(11):1546-53. doi:10.1111/dme.13451

74.

William H. Polonsky, Lawrence Fisher, Jay Earles, R. James Dudl, Joel Lees, Joseph Mullan. Assessing psychosocial distress in diabetes: development of the Diabetes Distress Scale. Diabetes Care [Internet]. Available from:
http://go.galegroup.com.ezproxy3.lib.le.ac.uk/ps/retrieve.do?tabID=T002&resultListType=RESULT_LIST&searchResultsType=SingleTab&searchType=AdvancedSearchForm¤tPosition=25&docId=GALE%7CA130282980&docType=Article&sort=Relevance&contentSegment=&prodId=EAIM&contentSet=GALE%7CA130282980&searchId=R15&userGroupName=leicester&inPS=true

75.

Constructs of depression and distress in diabetes: time for an appraisal- ClinicalKey [Internet]. Available from:
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858715001357>

76.

Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. Textbook of Diabetes [Internet]. 5th ed. Somerset: John Wiley & Sons, Incorporated; 2016. Available from: <http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

77.

Holt RIG. Textbook of diabetes [Internet]. 4th ed. Chichester: Wiley-Blackwell; 2010. Available from: <http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

78.

Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, von Eynatten M, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. *The Lancet*. 2012 Aug;380(9840):475–83. doi:10.1016/S0140-6736(12)60691-6

79.

Rizos CV, Kei A, Elisaf MS. The current role of thiazolidinediones in diabetes management. *Archives of Toxicology*. 2016 Aug;90(8):1861–81. doi:10.1007/s00204-016-1737-4

80.

Nissen SE, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. *New England Journal of Medicine*. 2007 Jun 14;356(24):2457–71. doi:10.1056/NEJMoa072761

81.

Tanner M. Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulphonylureas increases hypoglycemia. *Annals of Internal Medicine*. 2016 Aug 16;165(4). doi:10.7326/ACPJC-2016-165-4-020

82.

Mishriky BM, Cummings DM, Tanenberg RJ. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. *Diabetes Research and Clinical Practice*. 2015 Aug;109(2):378-88. doi:10.1016/j.diabres.2015.05.025

83.

Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, et al. Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations. *Annals of Internal Medicine*. 2011 May 3;154(9). doi:10.7326/0003-4819-154-9-201105030-00336

84.

Merlin C. Thomas. Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment. *Diabetes Therapy*. 2016;7(3). doi:doi: 10.1007/s13300-016-0189-4

85.

Paul Craddy. Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison. *Diabetes Therapy*. 2014;5(1). doi:doi: 10.1007/s13300-014-0061-3

86.

Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. *Textbook of Diabetes* [Internet]. 5th ed. Somerset: John Wiley & Sons, Incorporated; 2016. Available from: <http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

87.

Holt RIG. *Textbook of diabetes* [Internet]. 4th ed. Chichester: Wiley-Blackwell; 2010. Available from: <http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

88.

Ryder B, McKnight J, Blann A, Dhatariya K, Gregory R, Robinson T, et al. ABCD position

statement on GLP-1 based therapies and pancreatic damage. Practical Diabetes. 2013 Nov;30(9):388–91. doi:10.1002/pdi.1816

89.

Amori RE, Lau J, Pittas AG. Efficacy and Safety of Incretin Therapy in Type 2 Diabetes. JAMA. 2007 Jul 11;298(2). doi:10.1001/jama.298.2.194

90.

Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). The Lancet. 2009 Jul;374(9683):39–47. doi:10.1016/S0140-6736(09)60659-0

91.

Type 2 diabetes: prevention in people at high risk | Guidance and guidelines | NICE [Internet]. Available from: <http://www.nice.org.uk/guidance/PH38>

92.

Buse JB, Drucker DJ, Taylor KL, Kim T, Walsh B, Hu H, et al. DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks. Diabetes Care. 2010 Jun 1;33(6):1255–61. doi:10.2337/dc09-1914

93.

Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AYM, et al. Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients With Type 2 Diabetes. Annals of Internal Medicine. 2011 Jan 18;154(2). doi:10.7326/0003-4819-154-2-201101180-00300

94.

Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. The Lancet. 2010 Jun;375(9733):2223–33. doi:10.1016/S0140-6736(10)60407-2

95.

Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. *The Lancet*. 2010 Jun;375(9733):2234-43. doi:10.1016/S0140-6736(10)60406-0

96.

Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. *Diabetes, Obesity and Metabolism*. 2007 Mar;9(2):194-205. doi:10.1111/j.1463-1326.2006.00704.x

97.

Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes | 1-Recommendations | Guidance and guidelines | NICE [Internet]. Available from: <https://www.nice.org.uk/guidance/ta390/chapter/1-Recommendations>

98.

Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *New England Journal of Medicine*. 2016 Sep 15. doi:10.1056/NEJMoa1607141

99.

Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. *The Lancet Diabetes & Endocrinology*. 2016 Jun;4(6):525-36. doi:10.1016/S2213-8587(15)00482-9

100.

Type 2 diabetes: lixisenatide | Evidence-review | Advice | NICE [Internet]. Available from: <https://www.nice.org.uk/advice/esnm26/chapter/evidence-review>

101.

Dapagliflozin in combination therapy for treating type 2 diabetes June 2013 [Internet]. Available from: <http://www.nice.org.uk/guidance/ta288>

102.

Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes | Guidance and guidelines TA 248 Feb 2015 [Internet]. Available from: <https://www.nice.org.uk/guidance/ta248>

103.

Liraglutide for the treatment of type 2 diabetes mellitus. TA203, Oct 2010 [Internet]. Available from: <https://www.nice.org.uk/guidance/ta203>

104.

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2016 Jul 28;375(4):311–22. doi:10.1056/NEJMoa1603827

105.

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2016 Nov 3;375(18):1797–9. doi:10.1056/NEJMc1611289

106.

Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. New England Journal of Medicine. 2016 Jul 28;375(4):323–34. doi:10.1056/NEJMoa1515920

107.

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. New England Journal of Medicine. 2016 Nov 3;375(18):1799–802. doi:10.1056/NEJMc1611290

108.

Courtney H, Nayar R, Rajeswaran C, Jandhyala R. Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*. 2017 Mar;Volume 10:79–87.
doi:10.2147/DMSO.S126763

109.

Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*. 2015 Jul 16;373(3):232–42. doi:10.1056/NEJMoa1501352

110.

Rotz ME, Ganetsky VS, Sen S, Thomas TF. Implications of incretin-based therapies on cardiovascular disease. *International Journal of Clinical Practice*. 2015 May;69(5):531–49.
doi:10.1111/ijcp.12572

111.

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*. 2016 Jul 28;375(4):311–22. doi:10.1056/NEJMoa1603827

112.

Levin PA, Nguyen H, Wittbrodt E, Kim SC. Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*. 2017 Apr;Volume 10:123–39.
doi:10.2147/DMSO.S130834

113.

Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. *Textbook of Diabetes* [Internet]. 5th ed. Somerset: John Wiley & Sons, Incorporated; 2016. Available from:
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

114.

Holt RIG. Textbook of diabetes [Internet]. 4th ed. Chichester: Wiley-Blackwell; 2010.
Available from: <http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

115.

Leff DR, Heath D. Surgery for obesity in adulthood. *BMJ*. 2009 Sep 22;339(sep22 1):b3402-b3402. doi:10.1136/bmj.b3402

116.

Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, et al. Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes. *New England Journal of Medicine*. 2012 Apr 26;366(17):1567-76. doi:10.1056/NEJMoa1200225

117.

Riddle MC, Aronson R, Home P, Marre M, Niemoeller E, Miossec P, et al. Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L). *Diabetes Care*. 2013 Sep 1;36(9):2489-96. doi:10.2337/dc12-2454

118.

Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery. *New England Journal of Medicine*. 2004 Dec 23;351(26):2683-93. doi:10.1056/NEJMoa035622

119.

Persaud SJ, Jones PM. A Wake-up Call for Type 2 Diabetes? *New England Journal of Medicine*. 2016 Sep 15;375(11):1090-2. doi:10.1056/NEJMcibr1607950

120.

Fagin JA, Wells SA. Biologic and Clinical Perspectives on Thyroid Cancer. *New England Journal of Medicine*. 2016 Sep 15;375(11):1054-67. doi:10.1056/NEJMra1501993

121.

National Obesity Observatory [Internet]. Available from: <http://www.noo.org.uk>

122.

Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. *New England Journal of Medicine*. 2017 Feb 16;376(7):641–51. doi:10.1056/NEJMoa1600869

123.

Min SH, Yoon JH, Hahn S, Cho YM. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis. *Diabetes/Metabolism Research and Reviews*. 2017 Jan;33(1). doi:10.1002/dmrr.2818

124.

Dungan KM, Povedano ST, Forst T, González JGG, Atisso C, Sealls W, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. *The Lancet*. 2014 Oct;384(9951):1349–57. doi:10.1016/S0140-6736(14)60976-4

125.

Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). *Diabetes Care*. 2014 Aug;37(8):2149–58. doi:10.2337/dc13-2761

126.

Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. *New England Journal of Medicine*. 2017 Feb 16;376(7):641–51. doi:10.1056/NEJMoa1600869

127.

Bethel MA, Engel SS, Green JB, Huang Z, Josse RG, Kaufman KD, et al. Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). *Diabetes Care*. 2017 Apr;40(4):494-501. doi:10.2337/dc16-1135

128.

Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. *Textbook of Diabetes* [Internet]. 5th ed. Somerset: John Wiley & Sons, Incorporated; 2016. Available from: <http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

129.

Holt RIG. *Textbook of diabetes* [Internet]. 4th ed. Chichester: Wiley-Blackwell; 2010. Available from: <http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

130.

Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, et al. Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. *New England Journal of Medicine*. 2010 Jul 22;363(4):311-20. doi:10.1056/NEJMoa1002853

131.

Choudhary P, Parrott NR, Birtles L, Rutter MK. Islet cell transplantation: current status in the UK (2012). *Practical Diabetes*. 2012 Sep;29(7):280-5. doi:10.1002/pdi.1707

132.

Pickup JC. Insulin-Pump Therapy for Type 1 Diabetes Mellitus. *New England Journal of Medicine*. 2012 Apr 26;366(17):1616-24. doi:10.1056/NEJMct1113948

133.

Srinivasan P, Huang GC, Amiel SA, Heaton ND. Islet cell transplantation. *Postgraduate Medical Journal*. 2007 Apr 1;83(978):224-9. doi:10.1136/pgmj.2006.053447

134.

Liraglutide for the treatment of type 2 diabetes mellitus. TA203, Oct 2010 [Internet]. Available from: <https://www.nice.org.uk/guidance/ta203>

135.

Villani M, de Courten B, Zoungas S. Emergency treatment of hypoglycaemia: a guideline and evidence review. *Diabetic Medicine*. 2017 Sep;34(9):1205–11. doi:10.1111/dme.13379

136.

Dhatariya KK, Skedgel C, Fordham R. The cost of treating diabetic ketoacidosis in the UK: a national survey of hospital resource use. *Diabetic Medicine*. 2017 Oct;34(10):1361–6. doi:10.1111/dme.13427

137.

Leelarathna L, Roberts SA, Hindle A, Markakis K, Alam T, Chapman A, et al. Comparison of different insulin pump makes under routine care conditions in adults with Type 1 diabetes. *Diabetic Medicine*. 2017 Oct;34(10):1372–9. doi:10.1111/dme.13412

138.

Yates T, Davies MJ. Physical activity and Type 1 diabetes: an underused therapy. *Diabetic Medicine*. 2017 Nov;34(11):1498–9. doi:10.1111/dme.13445

139.

Narendran P, Jackson N, Daley A, Thompson D, Stokes K, Greenfield S, et al. Exercise to preserve β -cell function in recent-onset Type 1 diabetes mellitus (EXTOD) - a randomized controlled pilot trial. *Diabetic Medicine*. 2017 Nov;34(11):1521–31. doi:10.1111/dme.13439

140.

Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. Textbook of Diabetes [Internet]. 5th ed. Somerset: John Wiley & Sons, Incorporated; 2016. Available from: <http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

141.

Holt RIG. Textbook of diabetes [Internet]. 4th ed. Chichester: Wiley-Blackwell; 2010. Available from: <http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

142.

Exercise and Glucose Metabolism in Persons with Diabetes Mellitus: Perspectives on the Role for Continuous Glucose Monitoring. Journal of diabetes science and technology (Online) [Internet]. 3(4). Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769951/>

143.

Minimizing Hypoglycemia in Diabetes: Table 1. Diabetes Care. 2015 Aug;38(8):1583–91. doi:10.2337/dc15-0279

144.

[ARCHIVED CONTENT] Medicines management: Everybody's business : Department of Health - Publications and statistics [Internet]. Available from: http://webarchive.nationalarchives.gov.uk/20080205132320/http://dh.gov.uk/en/publication/sandstatistics/publications/publicationspolicyandguidance/dh_082200

145.

Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. CG76, Jan 2009 [Internet]. Available from: <https://www.nice.org.uk/guidance/cg76>

146.

Grammes J, Stock W, Mann CG, Flynn EM, Kubiak T. Focus group study to identify the central facets of fear of hypoglycaemia in people with Type 2 diabetes mellitus. Diabetic

Medicine. 2017 Aug 30. doi:10.1111/dme.13506

147.

Sivasubramaniyam S, Amiel SA, Choudhary P. Proportion of daily capillary blood glucose readings required in the target range for target glycaemic control: shift of focus from target range to proportion in range. *Diabetic Medicine*. 2017 Oct;34(10):1456–60. doi:10.1111/dme.13438

148.

Vloemans AF, van Beers CAJ, de Wit M, Cleijne W, Rondags SM, Geelhoed-Duijvestijn PH, et al. Keeping safe. Continuous glucose monitoring (CGM) in persons with Type 1 diabetes and impaired awareness of hypoglycaemia: a qualitative study. *Diabetic Medicine*. 2017 Oct;34(10):1470–6. doi:10.1111/dme.13429

149.

Harman-Boehm I. Continuous glucose monitoring in type 2 diabetes. *Diabetes Research and Clinical Practice*. 2008 Dec;82:S118–21. doi:10.1016/j.diabres.2008.09.051

150.

Bailey, Stephen. *Academic Writing : A Handbook for International Students* [Internet]. Available from: <http://lib.myilibrary.com.ezproxy4.lib.le.ac.uk/Open.aspx?id=310467>

151.

Creame P, Lea MR. *Writing At University: A Guide For Students* [Electronic resource]. 3rd ed. Maidenhead: McGraw-Hill Education; 2008. Available from: <https://ebookcentral.proquest.com/lib/leicester/detail.action?pq-origsite=primo&docID=345134>